The level of CCL2 in patients with prostate cancer was significantly higher than those without prostate cancer in all PSA ranges ( < 41, < 20, < 10, 4-41, 4-20, and 4-10 ng/mL) (Supplementary Table S1). This evidence concerns the gene CCL2 and prostate carcinoma.